Product Description
Mechanisms of Action: ADRA2A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Approved
Approved Countries: Egypt | Pakistan | Taiwan | United States
Approved Indications: None
Known Adverse Events: None
Company: Cairo University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Anesthesia Related
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT05875519 | N/A |
Completed |
Anesthesia Related |
2023-11-20 |
|
local anesthesia in chilldren | P3 |
Completed |
Anesthesia Related |
2021-09-30 |
|
NTALJ | N/A |
Unknown status |
Other |
2019-09-16 |